1. Home
  2. RCEL vs BRW Comparison

RCEL vs BRW Comparison

Compare RCEL & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • BRW
  • Stock Information
  • Founded
  • RCEL N/A
  • BRW 1987
  • Country
  • RCEL United States
  • BRW United States
  • Employees
  • RCEL 260
  • BRW N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • BRW Trusts Except Educational Religious and Charitable
  • Sector
  • RCEL Health Care
  • BRW Finance
  • Exchange
  • RCEL Nasdaq
  • BRW Nasdaq
  • Market Cap
  • RCEL 136.7M
  • BRW 333.0M
  • IPO Year
  • RCEL N/A
  • BRW N/A
  • Fundamental
  • Price
  • RCEL $5.71
  • BRW $8.12
  • Analyst Decision
  • RCEL Strong Buy
  • BRW
  • Analyst Count
  • RCEL 4
  • BRW 0
  • Target Price
  • RCEL $16.50
  • BRW N/A
  • AVG Volume (30 Days)
  • RCEL 308.7K
  • BRW 222.1K
  • Earning Date
  • RCEL 08-07-2025
  • BRW 01-01-0001
  • Dividend Yield
  • RCEL N/A
  • BRW 15.59%
  • EPS Growth
  • RCEL N/A
  • BRW N/A
  • EPS
  • RCEL N/A
  • BRW N/A
  • Revenue
  • RCEL $71,661,000.00
  • BRW N/A
  • Revenue This Year
  • RCEL $57.16
  • BRW N/A
  • Revenue Next Year
  • RCEL $36.69
  • BRW N/A
  • P/E Ratio
  • RCEL N/A
  • BRW N/A
  • Revenue Growth
  • RCEL 41.35
  • BRW N/A
  • 52 Week Low
  • RCEL $4.71
  • BRW $7.15
  • 52 Week High
  • RCEL $14.16
  • BRW $8.30
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 49.89
  • BRW 65.91
  • Support Level
  • RCEL $5.13
  • BRW $8.06
  • Resistance Level
  • RCEL $5.87
  • BRW $8.18
  • Average True Range (ATR)
  • RCEL 0.31
  • BRW 0.08
  • MACD
  • RCEL 0.14
  • BRW 0.00
  • Stochastic Oscillator
  • RCEL 83.19
  • BRW 82.86

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

Share on Social Networks: